ストックスクリーナーアプリを入手
2.03
2.53%
0.05
前日終値:
$1.98
開ける：
$2.01
24時間の取引高:
104.47K
Relative Volume:
0.40
時価総額：
$2.96B
収益：
-
当期純損益:
-
株価収益率:
-9.0343
EPS:
-0.2247
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+9.73%
1か月 パフォーマンス:
+40.00%
6か月 パフォーマンス:
-0.98%
1年 パフォーマンス:
-30.48%
1日の値動き範囲:
$1.95
$2.09
1週間の範囲:
$1.78
$2.15
52週間の値動き範囲:
$1.32
$3.335
Immutep Limited Adr Stock (IMMP) Company Profile
IMMP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
2.03 | 269.28M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-17 | 開始されました | CapitalOne | Overweight |
| 2023-08-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-07-16 | 再開されました | Maxim Group | Buy |
| 2018-09-28 | 開始されました | B. Riley FBR | Buy |
| 2018-02-15 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Immutep Limited Adr (IMMP) 最新ニュース
Market Highlights: Immutep Limited ADR (IMMP) Ends on a Low Note at 1.93 - DWinneX
Immutep stock soars on promising trial results By Investing.com - Investing.com Nigeria
Immutep stock soars on promising trial results - Investing.com Australia
Immutep Quarterly Activities Report Q3 FY25 - The Manila Times
Immutep to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Immutep Limited (ASX:IMM) Initiates Phase III Trial for Non-Small Cell Lung Cancer - thecapitalclub.com.au
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - Yahoo Finance
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - Yahoo Finance
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewswire
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - Targeted Oncology
Best Penny Stocks To Buy For 2021? 5 Biotech Stocks To Watch - Penny Stocks
IMMPImmutep Latest Stock News & Market Updates - Stock Titan
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Immutep Ltd (IMMP) Stock Price, Trades & News - GuruFocus
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
A Full List of Australia ADRs - Investing.com Australia
Immutep (IMMP) Stock Price, News & Analysis - MarketBeat
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com
Prima BioMed Stock Price Today | NASDAQ IMMP - Investing.com Canada
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - advfn.com
Immutep Limited Adr (IMMP) 財務データ
Immutep Limited Adr (IMMP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):